Gunnar Juliusson
21 – 30 of 159
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Epidemiology and Etiology of AML
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Subcutaneous cladribine to treat multiple sclerosis : experience in 208 patients
- Contribution to journal › Article
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
- Contribution to journal › Article
-
Mark
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : The HOVON-SAKK-132 trial
- Contribution to journal › Article
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
- Contribution to journal › Article
-
Mark
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
- Contribution to journal › Article
-
Mark
Impact of treatment delay in acute myeloid leukemia revisited
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
- Contribution to journal › Article
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
- Contribution to journal › Article
-
Mark
Hypo, Hyper, or Combo : New paradigm for treatment of acute myeloid leukemia in older people
- Contribution to journal › Scientific review
